{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-027925","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.622587+00:00","generated_at":"2026-06-05T01:48:18.604769+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ALX Oncology Q4 2023 net loss $45.5M; cash $218.1M; ASPEN-06 interim ORR 52%","bullets":["GAAP net loss Q4 2023: $45.5M ($0.93/share); FY 2023 net loss $160.8M ($3.74/share).","Cash, equivalents, investments $218.1M at Dec 31, 2023; runway into early 2026.","R&D expenses Q4 2023: $41.8M (up from $25.2M Q4 2022) due to more active trials.","ASPEN-06 interim: ORR 52% evorpacept combo vs 22% control; mDOR not reached vs 7.4 mo.","Anticipated milestones: ASPEN-06 top-line all 122 subjects June-July 2024; Phase 3 start Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-027925","json":"https://secwatch.observer/filing/0000950170-24-027925.json","markdown":"https://secwatch.observer/filing/0000950170-24-027925.md","text":"https://secwatch.observer/filing/0000950170-24-027925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024027925/0000950170-24-027925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024027925/alxo-20240307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:48:18.604769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"241a667d7618158b64281557a75c6b64fa422e0b","claim":"ALX ONCOLOGY HOLDINGS INC reported the fourth quarter and full year ended December 31, 2023 results: net income GAAP net loss was $45.5 million for the fourth quarter ended December 31, 2023, or ($0.93) per basic and diluted share, EPS ($0.93) per basic and diluted share.","evidence_excerpt":"On March 7, 2024, ALX Oncology Holdings Inc. (the \"Company\"), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024027925/0000950170-24-027925-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"GAAP net loss was $45.5 million for the fourth quarter ended December 31, 2023, or ($0.93) per basic and diluted share"},{"label":"EPS","value":"($0.93) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}